X4 Pharmaceuticals Inc
For the period ended May 1, 2025. Filed May 1, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 1, 2025 · Filed May 1, 2025
Use the contents to explore the available documents and sections.
XFOR$3.18+3.6%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Strategic Restructuring
Strategic Restructuring
In February 2025, X4 announced a strategic restructuring to sharpen focus and maximize the opportunity for mavorixafor in chronic neutropenia while also optimizing its U.S. promotion of XOLREMDI. X4 continues to expect that these efforts will decrease spending by $30-35 million annually.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.